KR102360938B1 - 새로운 만성 궤양 치료제 - Google Patents

새로운 만성 궤양 치료제 Download PDF

Info

Publication number
KR102360938B1
KR102360938B1 KR1020167016272A KR20167016272A KR102360938B1 KR 102360938 B1 KR102360938 B1 KR 102360938B1 KR 1020167016272 A KR1020167016272 A KR 1020167016272A KR 20167016272 A KR20167016272 A KR 20167016272A KR 102360938 B1 KR102360938 B1 KR 102360938B1
Authority
KR
South Korea
Prior art keywords
wound
treatment
dose
formulation
ulcer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167016272A
Other languages
English (en)
Korean (ko)
Other versions
KR20160088914A (ko
Inventor
알바 그뤤버그
알바 그?拈仄?
크리스틴 디에테리치
마지트 말라푸
Original Assignee
페가수스 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페가수스 아베 filed Critical 페가수스 아베
Publication of KR20160088914A publication Critical patent/KR20160088914A/ko
Application granted granted Critical
Publication of KR102360938B1 publication Critical patent/KR102360938B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
KR1020167016272A 2013-11-19 2014-11-19 새로운 만성 궤양 치료제 Expired - Fee Related KR102360938B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBPCT/GB2013/053053 2013-11-19
PCT/GB2013/053053 WO2015075406A1 (en) 2013-11-19 2013-11-19 New treatment of chronic ulcers
PCT/GB2014/053415 WO2015075441A1 (en) 2013-11-19 2014-11-19 New treatment of chronic ulcers

Publications (2)

Publication Number Publication Date
KR20160088914A KR20160088914A (ko) 2016-07-26
KR102360938B1 true KR102360938B1 (ko) 2022-02-09

Family

ID=49998562

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167016272A Expired - Fee Related KR102360938B1 (ko) 2013-11-19 2014-11-19 새로운 만성 궤양 치료제

Country Status (15)

Country Link
US (3) US10226508B2 (enExample)
EP (1) EP3071216B1 (enExample)
JP (1) JP6539268B2 (enExample)
KR (1) KR102360938B1 (enExample)
CN (1) CN105939726A (enExample)
AU (1) AU2014351607B2 (enExample)
BR (1) BR112016011166A8 (enExample)
CA (1) CA2927557C (enExample)
ES (1) ES2925876T3 (enExample)
MX (1) MX379357B (enExample)
PL (1) PL3071216T3 (enExample)
RU (1) RU2707254C1 (enExample)
TW (1) TWI698251B (enExample)
WO (2) WO2015075406A1 (enExample)
ZA (1) ZA201604110B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0808376D0 (en) 2008-05-08 2008-06-18 Bristol Myers Squibb Co Wound dressing
GB0817796D0 (en) 2008-09-29 2008-11-05 Convatec Inc wound dressing
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
CA2819475C (en) 2010-12-08 2019-02-12 Convatec Technologies Inc. Integrated system for assessing wound exudates
DK2648795T3 (da) 2010-12-08 2023-03-27 Convatec Technologies Inc System til fjernelse af eksudater fra en sårposition
CN103347562B (zh) 2010-12-08 2016-08-10 康沃特克科技公司 伤口分泌液系统附件
GB201115182D0 (en) 2011-09-02 2011-10-19 Trio Healthcare Ltd Skin contact material
GB2497406A (en) 2011-11-29 2013-06-12 Webtec Converting Llc Dressing with a perforated binder layer
GB201120693D0 (en) 2011-12-01 2012-01-11 Convatec Technologies Inc Wound dressing for use in vacuum therapy
MX2015007771A (es) 2012-12-20 2015-09-04 Convatec Technologies Inc Procesamiento de fibras celulosicas quimicamente modificadas.
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
AU2016256436B2 (en) 2015-04-28 2020-10-22 Convatec Technologies Inc. Antibacterial nanofibres
GB2543544A (en) 2015-10-21 2017-04-26 Brightwake Ltd Wound dressing
JP7183146B2 (ja) 2016-03-30 2022-12-05 コンバテック・テクノロジーズ・インコーポレイテッド 創傷における微生物感染の検出
JP2019513238A (ja) 2016-03-30 2019-05-23 クオリザイム・ダイアグノスティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＱｕａｌｉｚｙｍｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｇｍｂｈ Ａｎｄ Ｃｏ． Ｋｇ 創傷における微生物感染の検出
GB201608099D0 (en) 2016-05-09 2016-06-22 Convatec Technologies Inc Negative pressure wound dressing
KR20190026858A (ko) 2016-07-08 2019-03-13 컨바텍 테크놀러지스 인크 가요성 부압 시스템
DK3481360T3 (da) 2016-07-08 2022-03-28 Convatec Technologies Inc Fluidstrømningsmåling
BR112019000284A2 (pt) 2016-07-08 2019-04-16 Convatec Technologies Inc. aparelho de coleta de fluido
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
MX2019014772A (es) 2017-06-12 2020-02-07 Lakewood Amedex Inc Formulaciones en gel de bisfosfocinas y usos de estas.
EP3710074B1 (en) 2017-11-16 2024-03-20 ConvaTec Limited Fluid collection apparatus
BR112021006954A2 (pt) 2018-10-17 2021-07-20 Lakewood Amedex, Inc. métodos e composições para tratar mucosite oral
EP3962544B1 (en) 2019-06-03 2023-11-08 Convatec Limited Methods and devices to disrupt and contain pathogens
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
EP0935965A4 (en) 1996-04-23 2002-01-23 Toray Industries SUBSTANCE AGAINST PYLORI
WO1998002196A1 (en) * 1996-07-11 1998-01-22 Coloplast A/S A hydrocolloid wound gel
US6861067B2 (en) 1998-09-17 2005-03-01 Sherwood Services Ag Hydrogel wound dressing and the method of making and using the same
US6835713B2 (en) 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
EP1358888A1 (en) 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7262179B2 (en) * 2003-05-28 2007-08-28 Bristol-Myers Squibb Company Wound care compositions
EP1621205A1 (en) * 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
ZA200600686B (en) * 2006-01-24 2006-04-26 Jacobus F Mouton A wound dressing
US20080226724A1 (en) * 2007-01-19 2008-09-18 Genentech, Inc. Prevention of hydrogel viscosity loss
KR20100049039A (ko) * 2007-06-25 2010-05-11 리포펩타이드 아베 신규한 의약제
AU2008289178A1 (en) * 2007-08-16 2009-02-26 Carnegie Mellon University Inflammation-regulating compositions and methods
ES2625145T3 (es) * 2007-12-28 2017-07-18 Augustinus Bader Aplicación tópica y formulación de eritropoyetina para cicatrizar heridas cutáneas
CA2779433A1 (en) * 2009-11-03 2011-05-12 Lipidor Ab Composition for promoting wound healing
JP2013537195A (ja) * 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
US9693936B2 (en) * 2012-03-07 2017-07-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dispersions in oil of Dead Sea nano sized material preparation and uses therof
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers

Also Published As

Publication number Publication date
CA2927557A1 (en) 2015-05-28
WO2015075441A1 (en) 2015-05-28
MX2016006091A (es) 2016-12-09
CA2927557C (en) 2023-05-02
PL3071216T3 (pl) 2022-11-21
RU2707254C1 (ru) 2019-11-25
AU2014351607B2 (en) 2020-03-05
BR112016011166A8 (pt) 2022-06-28
EP3071216A1 (en) 2016-09-28
TWI698251B (zh) 2020-07-11
KR20160088914A (ko) 2016-07-26
JP2016537373A (ja) 2016-12-01
JP6539268B2 (ja) 2019-07-03
WO2015075406A1 (en) 2015-05-28
MX379357B (es) 2025-03-11
US20190255147A1 (en) 2019-08-22
AU2014351607A1 (en) 2016-06-23
US10709760B2 (en) 2020-07-14
US11191810B2 (en) 2021-12-07
RU2016124234A (ru) 2017-12-25
ES2925876T3 (es) 2022-10-20
US10226508B2 (en) 2019-03-12
US20160271217A1 (en) 2016-09-22
CN105939726A (zh) 2016-09-14
TW201521760A (zh) 2015-06-16
ZA201604110B (en) 2020-11-25
BR112016011166A2 (enExample) 2017-08-08
US20200384077A1 (en) 2020-12-10
EP3071216B1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
US11191810B2 (en) Treatment of chronic ulcers
Belmin et al. Sequential treatment with calcium alginate dressings and hydrocolloid dressings accelerates pressure ulcer healing in older subjects: a multicenter randomized trial of sequential versus nonsequential treatment with hydrocolloid dressings alone
Alvarez et al. Incorporating wound healing strategies to improve palliation (symptom management) in patients with chronic wounds
KR20120022930A (ko) 은 설파디아진 및 키토산을 사용하여 제조한 약용 크림 및 이의 제조 방법
JP6169693B2 (ja) 次亜塩素酸およびアミノ酸を含む創傷およびびらんを治療するための製剤
Whitmont et al. Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo‐controlled, double‐blind pilot clinical trial
Jacobsen Topical wound treatments and wound‐care products
Scalise et al. Enzymatic debridement: is HA-collagenase the right synergy? Randomized double-blind controlled clinical trial in venous leg ulcers.
Liu et al. Application of crystalline cellulose membrane (Veloderm®) on split-thickness skin graft donor sites in burn or reconstructive plastic surgery patients
EP3710044B1 (en) Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing
CA3079544A1 (en) Topical composition for improved healing of open wounds
Karri et al. Understanding the implications of pharmaceutical excipients and additives in the treatment of diabetic foot ulcers
HK1229249B (en) New treatment of chronic ulcers
HK1229249A1 (en) New treatment of chronic ulcers
RU2848912C1 (ru) Способ консервативного этапного лечения трофических язв
Tamas et al. Clinical experience in partial thickness burns treatment using LMW-Hyaluronic acid topics
Elgayyar et al. Evaluation of chitosan impregnated with silver nanoparticles in the treatment of chronic venous leg ulcer: an open-label controlled study
Emadi et al. Efficacy of a novel repairing gel therapy for the management of chronic wounds: a single-center, self-controlled pilot trial
AU2024270538A1 (en) Use of oligosaccharide compounds for preventing the recurrence of neuro-ischemic wounds in diabetic patients
US20220362327A1 (en) Compositions and methods for wound healing
Bianchi Iodoflex and Iodosorb in the treatment of venous leg ulcers
Humbert et al. Allaert
IL303383A (en) Compositions and methods for treating wounds
Reddy Karri et al. Understanding the implications of pharmaceutical excipients and additives in the treatment of diabetic foot ulcers.
JPH04145019A (ja) 塩化リゾチーム含有貼付剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250205

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250205

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250205